{"entity":{"id":"nct06299839","kind":"trial","name":"PAS-004 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of PAS-004 run by Pasithea Therapeutics Corp., now recruiting.","summary":"PAS-004 in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT06299839 by Pasithea Therapeutics Corp., with 83 participants planned, started 2024-02-29. Conditions recorded: RAS Mutation, NF1 Mutation, RAF Mutation and Advanced Solid Tumors. Interventions recorded: PAS-004 Capsules and PAS-004 Tablets.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06299839","url":"https://clinicaltrials.gov/study/NCT06299839"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pas-004"],"companies":["pasithea-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06299839","phase":"1","setting":"A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in Patients With MAPK Pathway-driven Advanced Solid Tumors With a Documented RAS, NF1, or RAF Mutation or Patients Who Have Failed BRAF/MEK Inhibition","sponsor":"Pasithea Therapeutics Corp.","enrolled":83,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06299839/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pas-004","kind":"drug","name":"PAS-004","route":"/drugs/pas-004/"}],"company":[{"id":"pasithea-therapeutics","kind":"company","name":"Pasithea Therapeutics","route":"/companies/pasithea-therapeutics/"}]}}